RWA
NBIX icon

Redhawk Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Redhawk Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,639
Closed -$1.11M – 318
2024
Q3 		$1.11M Buy
9,639
+807
+9% +$111K 0.16% 124
2024
Q2 		$1.22M Sell
8,832
-1,080
-11% -$148K 0.19% 110
2024
Q1 		$1.37M Buy
9,912
+463
+5% +$63.2K 0.22% 89
2023
Q4 		$1.25M Buy
+9,449
New +$1.09M 0.24% 95

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Redhawk Wealth Advisors's NBIX Position: Q4 2024 in Review

Redhawk Wealth Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 9,639 shares — an estimated $1.11M sold.

Redhawk Wealth Advisors first reported a position in NBIX in Q4 2023 and held it in 4 quarters. The position peaked at $1.37M in Q1 2024. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Redhawk Wealth Advisors reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Redhawk Wealth Advisors sold 9,639 Neurocrine Biosciences shares in Q4 2024, an estimated $1.11M.
  • Redhawk Wealth Advisors first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 4 quarters.
  • Redhawk Wealth Advisors's Neurocrine Biosciences position peaked at $1.37M in Q1 2024.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Redhawk Wealth Advisors's 13F filing for Q4 2024, filed 14 Jan 2025.